Skip to main content
. 2018 Jan 30;3(1):1231–1243. doi: 10.1021/acsomega.7b01956

Figure 5.

Figure 5

Study of the concentration, size, and MexAB-OprM dependent inhibitory effects of antibiotic nanocarriers (AgMUNH-Oflx NPs) on the growth of (A–D) WT and (E–H) ΔABM cells. (A–D) Images of the modified LB medium cultured (a) without cells (blank control) and with WT cells containing (b–i) 0, 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 μM (A) unconjugated free Oflx alone and (b–h) 0.2, 0.4, 0.6, 0.8, 1.08, 1.62, 2.16 μM Oflx conjugated with Ag NPs of (B) 2.4 ± 0.7, (C) 13.0 ± 3.1, and (D) 92.6 ± 4.4 nm in diameter, respectively. (E–H) Images of the modified LB medium cultured (j) without cells (blank control) and with ΔABM cells containing (k–r) 0, 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, and 0.27 μM (E) unconjugated free Oflx alone and (k–r) 0.02, 0.04, 0.06, 0.08, 0.11, 0.14, and 0.27 μM Oflx conjugated with the Ag NPs of (F) 2.4 ± 0.7, (G) 13.0 ± 3.1, and (H) 92.6 ± 4.4 nm in diameter, respectively. The concentrations of Oflx conjugated onto the NPs are determined based on their conjugation ratios in Table 1. The concentration of AgMUNH2 NPs in (i) of (B–D) and (r) of (F–H) contain the same concentration of NPs as that in (h) and (q) for each type of NP in (B–D) and (F–H) but without Oflx (control experiments to study the effects of AgMUNH2 NPs).